EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2

M Senna iD, A Mostaghimi iD, M Ohyama, R Sinclair, Y Dutronc, W S Wu, G Yu, C Chiasserini, N Somani, K Holzwarth, B King iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von M Senna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lahey Hospital and Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Azetidines, Janus Kinase Inhibitors, Purines. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Efficacy of the Janus kinase (JAK) inhibitor baricitinib for severe alopecia areata (AA) continuously increased over 52 weeks in two Phase 3 trials. There are limited long‐term data on JAK inhibitors in AA.

Objectives

To evaluate efficacy and safety of baricitinib for severe AA through 104 weeks of continuous therapy.

Methods

Integrated data from the BRAVE‐AA1 and BRAVE‐AA2 Phase 3 trials included adults with Severity of Alopecia Tool (SALT) scores ≥50 (≥50% scalp hair loss) randomized to and continuously treated with 2‐mg or 4‐mg baricitinib through Week 104. Patients who qualified to remain on continuous treatment included subjects who achieved SALT score ≤20 at Week 52 (Week‐52 responders; 2‐mg: N = 65; 4‐mg: N = 129) and baricitinib 4‐mg‐treated patients who had SALT score >20 at Week 52 but achieved SALT score ≤20 at prior visit(s) and/or had significant improvement in eyebrow or eyelash hair growth relative to baseline by Week 52 (Week‐52 mixed responders; N = 110). Week‐104 outcomes included the proportion of patients achieving SALT score ≤20 (≤20% scalp hair loss). Data were censored after treatment discontinuation.

Results

Among baricitinib 4‐mg‐treated and baricitinib 2‐mg‐treated Week‐52 responders, 90.7% and 89.2%, respectively, maintained SALT score ≤20 at Week 104. Among Week‐52 mixed responders, 39.1% reached SALT score ≤20 by Week 104. Continued improvement in eyebrow and eyelash regrowth was observed across groups. The most frequent treatment‐emergent adverse events were COVID‐19, upper respiratory tract infection, headache, nasopharyngitis, acne, urinary tract infection and creatine phosphokinase increase.

Conclusions

Baricitinib demonstrated a high level of maintenance of efficacy over 104 weeks in patients with severe AA. Efficacy increased in Week‐52 mixed responders, illustrating that long‐term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataAzetidinesJanus Kinase InhibitorsPurinesSulfonamidesAdultHumansAlopeciaPyrazolesRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Substanzen

AzetidinesbaricitinibJanus Kinase InhibitorsPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Lahey Hospital and Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Sinclair Dermatology, Melbourne, Victoria, Australia.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: M Senna, A Mostaghimi, B King

Förderung

  • Eli Lilly and Company

Zitieren

APA

Senna, M., Mostaghimi, A., Ohyama, M., Sinclair, R., Dutronc, Y., Wu, W. S., Yu, G., Chiasserini, C., Somani, N., Holzwarth, K., & King, B. (2024). Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19665

Vancouver

Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, et al. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19665

BibTeX
@article{Senna2024,
  author = {Senna, M and Mostaghimi, A and Ohyama, M and Sinclair, R and Dutronc, Y and Wu, W S and Yu, G and Chiasserini, C and Somani, N and Holzwarth, K and King, B},
  title = {Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19665}
}
Kostenlos starten →